There are differences in the pharmacological properties of phenylhistamines and histaprodifens between guinea pig histamine H 1 receptor (gpH 1 R) and human histamine H 1 receptor (hH 1 R). The aim of this study was to analyze species-differences in more detail, focusing on histaprodifen derivatives and including the bovine histamine H 1 receptor (bH 1 R) and rat histamine H 1 receptor (rH 1 R). H 1 R species isoforms were co-expressed with the regulator of G-protein signalling, RGS4, in Sf9 insect cells. We performed [ 3 H]mepyramine binding assays and steady-state GTPase assays. For a novel class of histaprodifens, the chiral histaprodifens, unique species-differences between hH 1 R, bH 1 R, rH 1 R and gpH 1 R were observed. The chiral histaprodifens (8R) and (8S) were both partial agonists at gpH 1 R, but only (8R) was a partial agonist at the other H 1 R species isoforms. An additional phenyl group in chiral histaprodifens (10R and 10S, respectively) resulted in a switch from agonism at gpH 1 R to antagonism at hH 1 R, bH 1 R and rH 1 R. In general, histaprodifens showed the order of potency hH 1 R < bH 1 R < rH 1 R < gpH 1 R. An active-state model of gpH 1 R was generated with molecular dynamics simulations. Dimeric histaprodifen was docked into the binding pocket of gpH 1 R. Hydrogen bonds and electrostatic interactions were detected between dimeric histaprodifen and . We conclude the following. i) Chiral histaprodifens interact differentially with H 1 R species isoforms. ii) gpH 1 R and rH 1 R on one hand and hH 1 R and bH 1 R on the other hand resemble each other structurally and pharmacologically, and iii) histaprodifens interact with H 1 R at multiple sites.
Introduction
The histamine H 1 receptor (H 1 R) is a prototypical G-protein-coupled receptor (GPCR) that interacts with G q -proteins to activate phospholipase C (Hill et al., 1997) . H 1 R antagonists are clinically important for the treatment of allergic diseases and H 1 R agonists are experimental tools to analyze H 1 R function. Numerous H 1 R agonists are known, including small agonists derived from histamine and bulkier agonists like phenylhistamines (Zingel et al., 1995; Leschke et al., 1995) , ergolines (Bakker et al., 2004 , Pertz et al., 2006 and histaprodifens (Menghin et al., 2003) . Suprahistaprodifen (Menghin et al., 2003 ) is a highly potent agonist at the guinea-pig ileum (pEC 50 , 8.26 ). Based on those data, Striegl (2006) synthesized a novel series of suprahistaprodifen derivatives.
The highly conserved Asp 3.32 in transmembrane helix (TM) 3 (Ohta et al., 1994; Nonaka et al., 1998) , Lys 5.39 (Leurs et al., 1995; Bruysters et al., 2004; Jongejan and Leurs, 2005) , Thr 5.42 (Ohta et al., 1994; Leurs et al., 1994) , Asn 5.46 (Leurs et al., 1994; Ohta et al., 1994) and Phe 6.55 (Bruysters et al., 2004) (Wieland et al., 1999; Gillard et al., 2002) .
Phenylhistamines and histaprodifens (Seifert et al., 2003) and ergolines (Pertz et al., 2006) were studied at the recombinant guinea pig H 1 -receptor (gpH 1 R) and human H 1 -receptor (hH 1 R) expressed in Sf9 insect cell membranes by [ 3 H]mepyramine competition binding and G q -protein-catalyzed GTP hydrolysis. Those studies revealed substantial speciesdifferences between gpH 1 R and hH 1 R. Asn 2.61 acts as a selectivity switch between hH 1 R and gpH 1 R (Bruysters et al., 2005) .
To date, the cDNAs of 12 mammalian H 1 R species isoforms are known. A phylogenetic tree of H 1 R species isoforms is shown in Fig. 1 . The cDNAs of gpH 1 R (Traiffort et al., 1994) , hH 1 R (Fukui et al., 1994) , bovine H 1 R (bH 1 R) (Yamashita et al., 1991) and rat H 1 -receptor (rH 1 R) (Fujimoto et al., 1993) are available in our laboratory. at room temperature at 15,000g. Six hundred µl of the supernatant fluid of reaction mixtures were removed and 32 P i was determined by liquid scintillation counting.
The steady-state GTPase assay was performed in the agonist and antagonist mode. In the agonist mode the percentage of increase in GTP-hydrolysis relative to histamine was determined with increasing concentrations of each ligand from 0.1 nM -100 µM. In the antagonist mode, the percentage of GTP-hydrolysis was determined as described in agonist experiments, but assay tubes additionally contained 1 µM histamine.
Data analysis.
All data were analyzed with the software Prism 4.02 (GraphPad Software, San Diego, CA). K B and pK B values were calculated according to Cheng and Prusoff (1973) . All data are the means ± SEM of at least three independent experiments. To compare two pairs of data, the significance of the deviation of zero p was calculated using the t-test.
Construction of an active gpH 1 R model with dimeric histaprodifen in the binding pocket. A homology model of the inactive gpH 1 R was constructed as described (Straßer and Wittmann, 2007) . Additionally, essential internal water molecules were placed into the receptor model. Afterwards, the whole model was embedded into an environment consisting of: 104 1-palmitoyl-2-oleoyl-phosphatidylcholine molecules, 12675 intracellular and extracellular water molecules and 8 sodium and 25 chloride ions to achieve electroneutrality.
This template was used to generate a model of the active gpH 1 R based on the distance restraints given by Niv et al. (2006) . Therefore, we performed restrained MD simulations with the software package GROMACS 3.2 (van der Spoel, 2004) . This procedure will be described in detail elsewhere. Briefly, a positively charged dimeric histaprodifen (17) was manually docked into the proposed binding-pocket of the active gpH 1 R and one sodium ion was deleted to conserve electroneutrality. The whole simulation box was energetically minimized.
This article has not been copyedited and formatted. The final version may differ from this version. Thereafter, MD simulations were performed. The whole equilibration phase was divided in 12 cycles with different simulation times and position constraints as described in the following.
The constraints for the backbone atoms (bb), side chain atoms (sc) and ligand atoms (lig) are given in kJ mol -1 nm -2
. Cycle 1: 250 ps, bb 5000, sc 5000, lig 5000; cycle 2: 100 ps, bb 4000, sc 4000, lig 4000; cycle 3: 100 ps, bb 4000, sc 3000, lig 3000; cycle 4: 100 ps, bb 3000, sc 3000, lig 3000 ; cycle 5: 100 ps, bb 2000, sc 1000, lig 1000; cycle 6: 100 ps, bb 1000, sc 800, lig 800; cycle 7: 100 ps, bb 800, sc 600, lig 600; cycle 8: 100 ps, bb 600, sc 400, lig 400; (Fig. 4) . bH 1 R and rH 1 R exhibited strong bands at ~60 kDa. The increase by 4 kDa relative to the theoretical mass is probably due to N-glycosylation. hH 1 R showed a strong band at ~85 kDa, probably because of a higher degree of N-glycosylation. Additionally, weak bands were visible in a range from 25-30 kDa and at ~50 kDa. gpH 1 R showed very different behavior in migration;
i.e. a strong band was detected at 25 kDa, intermediate bands were visible at ~30 kDa and 36 kDa, and faint bands were detected at ~50 kDa and ~100 kDa, respectively. The results with hH 1 R and gpH 1 R are in accordance with previous studies from our laboratory (Seifert et al., 2003) .
Some of the differences in electrophoretic mobility between the four H 1 R species isoforms may be explained with different N-glycosylation states. At the N-terminus, the four species isoforms exhibit different numbers of N-glycosylation sites; hH 1 R (2), bH 1 R (3), rH 1 R (2) and gpH 1 R (1). In E2 (last amino acid), there is an additional potential N-glycosylation site in bH 1 R and rH 1 R since the homology model shows that this amino acid should be positioned at the surface of the receptor (Fig. 2) . (Chang et al., 1979; Aceves et al., 1985; Nakahata et al., 1986; Yamashita et al., 1991; Fujimoto et al., 1993; Gillard et al., 2003; Bruysters et al., 2005 (2) (2) at all four H 1 R species isoforms. Compounds (6) and (7) differ from each other in the substitution pattern of the imidazolyl moiety. The pK i values of these compounds were in a range from 6.33-7.11 at all four H 1 R species isoforms. The pK i value of suprahistaprodifen (7) at gpH 1 R was significantly higher than at hH 1 R (p = 0.0012). Otherwise, there were no significant differences between these two compounds at H 1 R species isoforms.
The additional methyl group in suprahistaprodifen in (R) and (S) configuration (compounds (8R) and (8S)) resulted in significant differences between species isoforms and the (R) and (S) configuration as well, as illustrated in Fig. 6 . There was no significant difference in the pK i values between (7) (8S) were significant lower (p = 0.0026 for hH 1 R and p = 0.0006 for gpH 1 R) at both species isoforms compared to the (R)-configuration of (8). The decrease amounted to ~0.8 log units at gpH 1 R, and ~0.7 log units at hH 1 R. In contrast, at bH 1 R and rH 1 R, the pK i values of (8R) and (8S) were significantly lower than of (7), but there was no significant difference between (8R) and (8S). Thus, the largest difference in affinity between the (R)-and (S)-configuration was found at gpH 1 R, followed by hH 1 R. The additional phenyl moiety in (9) did not result in significant differences in pK i values relative to suprahistaprodifen (7) at all four H 1 R species isoforms. Again, the highest pK i value was found at gpH 1 R, which was significantly higher than at hH 1 R (p = 0.0082) and bH 1 R (p = 0.0057). The pK i values between the related phenylsubstituted (10R) and (10S) did not significantly differ from each other at H 1 R species isoforms. At gpH 1 R, the pK i value of (9) was significantly higher than for (10R) or (10S) (p = 0.004 for (10R) and p = 0.0072 for (10S)). The pK i values of (11) and (12) were similar at each H 1 R species isoform. Compounds (13)- (16), possessing a different substitution pattern of the terminal imidazolyl moiety compared to suprahistaprodifen (7) in combination with a varying length of the (CH 2 )-spacer, showed decreased affinity compared to histaprodifen (2) at all four H 1 R species isoforms. Except for (13) at bH 1 R, the decrease of about 0.4-1 log units was significant (p < 0.01). For the largest histaprodifen known so far, dimeric histaprodifen (17), we observed significant increases in pK i values compared to histaprodifen (2) for bH 1 R, rH 1 R and gpH 1 R. The pK i values for histamine (1), suprahistaprodifen (7) and dimeric histaprodifen (17) at hH 1 R and gpH 1 R are in good accordance with data published for mammalian expression systems (Gillard et al., 2003; Bruysters et al., 2005) . without significant difference between these three species isoforms. However, the basal activity with bH 1 R (1.8 pmol/(mg min)) was significantly higher (p < 0.05) than with hH 1 R, rH 1 R and gpH 1 R. Additionally, the maximum stimulation with 100 µM histamine (1) relative to the basal activity (∆HA) was significantly higher (p < 0.0001) at bH 1 R than at hH 1 R, rH 1 R and gpH 1 R ( Table 4 (18) ranged from 7.66-8.96 (Table 4) . Only the pEC 50 values of bH 1 R and rH 1 R were significantly different from gpH 1 R (p < 0.0025).
Analysis of histaprodifens at H 1 R species isoforms in the steady-state GTPase assay. The results of the GTPase assays are summarized in Tables 5 (agonist mode) and 6 (antagonist mode). There were no significant differences in the pEC 50 values of the endogenous ligand histamine (1) among H 1 R species isoforms. Histaprodifen (2) was a partial agonist at all four species isoforms. At gpH 1 R and rH 1 R, the pEC 50 of (2) increased about 0.8 log units relative to histamine (1). In contrast, there was no significant difference in the pEC 50 values of histaprodifen (2) relative to histamine (1) at hH 1 R and bH 1 R. The pEC 50 values of (2) between gpH 1 R and hH 1 R (p = 0.0005) or bH 1 R (p = 0.0302) were significantly different.
However, there was no significant difference in the pEC 50 values of (2) between gpH 1 R and rH 1 R, which were higher than at hH 1 R and bH 1 R. Thus, the additional diphenylpropyl moiety in histaprodifen (2) compared to histamine increased the pEC 50 at gpH 1 R and rH 1 R but had no effect on hH 1 R and bH 1 R. The additional Cl (3) and F (4) substituent in the diphenylpropyl moiety of (3) had no significant influence on the pEC 50 relative to histaprodifen (2). The pEC 50 of (4) at gpH 1 R versus hH 1 R (p = 0.0102) and bH 1 R (p = 0.0121) and at rH 1 R versus hH 1 R (p = 0.0203) and bH 1 R (p = 0.0111) were significantly different. The pEC 50 of (2) compared to the pEC 50 of (5) at hH 1 R, bH 1 R and rH 1 R were not significantly different. In contrast, the pEC 50 of (5) relative to (2) was significantly different (p = 0.0006) at gpH 1 R.
These data show that the pEC 50 values of the small histaprodifens (2-5) were similar between gpH 1 R and rH 1 R and higher than at hH 1 R and bH 1 R. Compared to histamine (1), pEC 50 values increased at gpH 1 R and rH 1 R, but not at hH 1 R and bH 1 R, except for (5) at bH 1 R.
The additional imidazolyl moieties in the histaprodifen derivatives (6), (7) and (13) differ in the position of substitution. Compounds (6), (7) and (13) exhibited only small differences in pEC 50 values at H 1 R species isoforms compared to histaprodifen (2). Again, higher pEC 50 values were found at gpH 1 R and rH 1 R for (6), (7) and (13). The substitution position of the imidazolyl moiety had only a small influence on the pEC 50 values at a given species isoform. Compounds (11), (12) and (9) have additional moieties at the R 3 position compared to suprahistaprodifen (7). The pEC 50 values of (11) were only significantly different between gpH 1 R and bH 1 R (p = 0.0061). The additional ethyl group in (11) slightly decreased pEC 50 values at rH 1 R, but had a small increasing influence at gpH 1 R and hH 1 R with respect to suprahistaprodifen (7). There was no significant difference between the four H 1 R species isoforms with respect to the pEC 50 values of the thienylmethyl-substituted suprahistaprodifen (12). Again, the additional substituent slightly decreased the pEC 50 values relative to suprahistaprodifen (7). The pEC 50 value of (9) at gpH 1 R was significantly higher (p < 0.05) than at hH 1 R, bH 1 R and rH 1 R.
The chiral histaprodifens (8R) and (8S) showed partial agonism at gpH 1 R. The Renantiomer (8R) was significantly more potent than the S-enantiomer (8S) (p = 0.0068). Only well as the efficacies were significantly lower than at gpH 1 R (p < 0.05). The S-enantiomer (8S) showed antagonism at hH 1 R, bH 1 R and rH 1 R with similar pK B values (Table 6 ). Thus, the additional methyl group, introducing a center of chirality constitutes a unique agonism/antagonism-switch between the species (S-configuration (8S)) and within the species (R/S-configuration (8R), (8S)). Fig. 9 illustrates this switch for gpH 1 R and hH 1 R.
The enantiomeric compounds (10R) and (10S) were partial agonists with equal potency at gpH 1 R. The efficacy of the R-enantiomer (10R) was significantly higher (p = 0.0062) than of the S-enantiomer (10S). Both enantiomers were antagonists at hH 1 R, bH 1 R and rH 1 R. There were no significant differences in the pK B values between the R-enantiomer (10R) and the S-enantiomer (10S) at hH 1 R, bH 1 R and rH 1 R (Table 6 ). However, the pK B values for (10R) and (10S) were significantly higher at hH 1 R than at bH 1 R and at rH 1 R. At bH 1 R and rH 1 R, the pK B values are in the same range. Thus, this pair of enantiomers showed agonism/antagonism-switch between species.
In compounds (13)-(16) the length of the CH 2 -spacer was varied, resulting in differences in pEC 50 values of about 0.7 log units at each species isoform between the compounds of this series. Compound (15), with a (CH 2 ) 4 -spacer, showed the lowest potency at all four species isoforms. The highest potency in this series was evident for (13) or (14).
For dimeric histaprodifen (17), species-differences were detected for all pairs of H 1 R species isoforms (p < 0.05), except for the pairs gpH 1 R/rH 1 R and bH 1 R/rH 1 R. The potency increased in the order hH 1 R < bH 1 R < rH 1 R < gpH 1 R.
At gpH 1 R, all histaprodifens were partial agonists. The compounds showed E max values from 0.23-0.92. Only (10S) showed an E max value <0.5. E max values at gpH 1 R and rH 1 R were higher than at bH 1 R and hH 1 R in most cases. Additionally, the E max values between hH 1 R and bH 1 R on one hand and between rH 1 R and gpH 1 R on the other hand were similar.
This article has not been copyedited and formatted. The final version may differ from this version. For suprahistaprodifen (7) and the chiral histaprodifens (8R) and (8S) we found two possible orientations in the binding pocket. In orientation I, (7) interacts electrostatically with Asp-116 (TM3, 3.32), Ser-120 (TM3, 3.36), Lys-187 (E2, interaction with backbone carbonyl), and Tyr-432 (TM6, 6.51) (Fig. 10B) . The diphenyl propyl moiety is embedded in a pocket formed by 3.40) and 4.56) . In orientation II, (7) also interacts electrostatically with Asp-116 (TM3, 3.32), Ser-120 (TM3, 3.36), Lys-187 (E2, interaction with backbone carbonyl), and Tyr-432 (TM6, 6.51) ( a small individual pocket facing towards TM7 (Fig. 10D) . In orientation I, both enantiomers (8R) and (8S) fit well into the binding pocket. However, in orientation II only (8R) fits well because of a steric clash between the additional methyl group in (8S) and Ile-455 (TM7, 7.39). As consequence a slight movement of the Ile-455 (TM7, 7.39) towards the binding pocket was observed (see blue circle in Fig. 10D ).
Discussion
Pharmacological differences between hH 1 R, bH 1 R, rH 1 R and gpH 1 R concerning the interaction with chiral histaprodifens. Chiral histaprodifens (8R), (8S), (10R) and (10S) were also analyzed at the guinea-pig ileum (Striegl 2006) . All four compounds acted as partial agonists, and the R-enantiomers (8R) (pEC 50 = 7.67) and (10R) (pEC 50 = 7.36) were about one log unit more potent than the corresponding S-enantiomers (8S) (pEC 50 = 6.81) and (10S) (pEC 50 = 6.44). These results are in good agreement with the results obtained in the recombinant system (Table 5 and (Fig. 10C ).
The chiral histaprodifen (8R) fits well into the binding pocket in both orientations.
However, (8S) only fits well in orientation I due to a steric clash between the additional methyl group and Ile-455 (TM7, 7.39) (Fig. 10D) . At gpH 1 R the affinities of suprahistaprodifen (7) and the chiral histaprodifen (8R) are similar, whereas a decrease in affinity is observed for (8S). Based on these results two hypotheses can be proposed. First,
suprahistaprodifen (7) and the chiral histaprodifens (8R) and (8S) may only bind in
This article has not been copyedited and formatted. The final version may differ from this version. orientation II into the binding pocket. As a consequence of the sterical clash, the affinity of (8S) is decreased. Second, suprahistaprodifen (7) and the chiral histaprodifen (8R) may bind in orientations I and II, but (8S) may only bind in orientation I. Thus, the experimentally observed K i value for (7) and (8R) may result from summation of the K i values for orientations I and II, whereas the K i value for (8S) may only be derived from orientation I.
With our present experimental data we cannot distinguish which of the two hypotheses is correct. By analogy to our data, Dezi et al. (2007) discuss two possible orientations for some butyrophenone derivatives at the serotonin 5-HT 2A -receptor.
Molecular basis for pharmacological differences between hH 1 R, bH 1 R, rH 1 R and gpH 1 R. The alignment of the amino acid sequences is given in Fig. 2 . Therein, the amino acids which interact directly with dimeric histaprodifen (17) in gpH 1 R are highlighted. The same amino acids are found in hH 1 R, bH 1 R and rH 1 R, too. The only difference occurs in the E2-loop at position 187 (gpH 1 R) with a lysine in gpH 1 R but an aspartate in hH 1 R, bH 1 R and rH 1 R. However, our simulations showed that dimeric histaprodifen (17) forms a stable hydrogen bond only to the backbone of Lys-187 in gpH 1 R, but not to the side chain, which is pointing away from the binding pocket. Thus, the differences in this position should not be responsible for the observed species-differences in pharmacology.
The alignment shows a difference between gpH 1 R versus hH 1 R, bH 1 R and rH 1 R in TM2 in position 2.61. In hH 1 R, bH 1 R and rH 1 R, there is an asparagine, which is changed to a serine in the gpH 1 R. Bruysters et al. (2005) reported that this mutation is responsible for species-differences between gpH 1 R and hH 1 R concerning suprahistaprodifen (7) and dimeric histaprodifen (17). Our studies showed an analogous species-difference in pK i values of suprahistaprodifen (7) and dimeric histaprodifen (17) between hH 1 R and gpH 1 R. If the amino acid exchange in position 2.61 alone had been exclusively responsible for the observed species-differences between hH 1 R and gpH 1 R, the pK i values of dimeric histaprodifen (17) at This article has not been copyedited and formatted. The final version may differ from this version. Table 1 , where the level of similarity of the amino acid sequences between hH 1 R, bH 1 R, rH 1 R and gpH 1 R is given.
Our studies support the usefulness of GPCR species isoforms as tools to analyze the binding mode of ligands. However, our data also clearly show that in some cases, it is difficult to explain species-differences in pharmacology with a single defined difference in amino acid sequence. Finally, the chiral histaprodifens are novel unique ligands to dissect subtle differences in the activation mechanism of the H 1 R in various species.
This article has not been copyedited and formatted. The final version may differ from this version. histaprodifens (2) - (5), large histaprodifens (6) - (17) and mepyramine (18). Table 3 .
This article has not been copyedited and formatted. The final version may differ from this version. Table 3 . Affinities of histamine and histaprodifens at hH 1 R, bH 1 R, rH 1 R and gpH 1 R coexpressed with RGS4 in Sf9 cell membranes in the competition binding assay.
[ Table 4 . Analysis of the effects of histamine and mepyramine and determination of the constitutive activity of hH 1 R, bH 1 R, rH 1 R and gpH 1 R in the steady-state GTPase assay.
Sf9 cell membranes expressing hH 1 R, bH 1 R, rH 1 R or gpH 1 R in combination with RGS4 were used to study the constitutive activity. GTPase assays were performed as described under
Methods. The concentration-response curves of the inverse agonist mepyramine (MEP) (18) were determined in a concentration range from 0.1 nM -10 µM. Data were analyzed by nonlinear regression and were best fit to sigmoidal concentration-response curves. The efficacy of histamine was set 1.00. The 
